儿科患者移植后淋巴细胞增生性疾病：爱尔兰的视角——单中心经验
Post-transplant lymphoproliferative disorder in paediatric patients: the Irish perspective-a single centre experience.
作者信息
Malone A, Kennedy G, Storey L, O'Marcaigh A, McDermott M, Broderick A M, Smith O P
机构信息
Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland.
University College Dublin, Dublin, Ireland.
出版信息
Ir J Med Sci. 2017 May;186(2):339-343. doi: 10.1007/s11845-016-1425-7. Epub 2016 Feb 29.
BACKGROUND
Post-transplant lymphoproliferative disease (PTLD) is a serious complication of both solid organ and haematopoietic stem cell transplantation in children. Its incidence has increased over the last decade as a result of more potent immunosuppressive regimens. Many treatments have been explored however optimal therapy remains controversial.
AIMS
We report on the diagnosis, treatment and outcome of ten patients who were diagnosed with PTLD in Our Lady's Hospital for Sick Children in Dublin between 2004 and 2015 inclusive.
METHODS
Data were collected by retrospective review of patient medical records.
RESULTS
9 out of ten of our patients are alive and disease free following treatment for PTLD with rituximab alone or in combination with chemotherapy.
CONCLUSION
The outcome of paediatric patients treated for PTLD at our institution is at least comparable to published international series and supports the use of rituximab ± low dose chemotherapy in the treatment of this malignancy.
背景
移植后淋巴细胞增殖性疾病（PTLD）是儿童实体器官移植和造血干细胞移植的一种严重并发症。在过去十年中，由于更有效的免疫抑制方案，其发病率有所上升。虽然已经探索了许多治疗方法，但最佳治疗方案仍存在争议。
目的
我们报告了2004年至2015年（含）期间在都柏林圣母儿童医院被诊断为PTLD的10例患者的诊断、治疗及预后情况。
方法
通过回顾性查阅患者病历收集数据。
结果
我们的10例患者中有9例在单独使用利妥昔单抗或联合化疗治疗PTLD后存活且无疾病。
结论
在我们机构接受PTLD治疗的儿科患者的预后至少与已发表的国际系列研究相当，并支持使用利妥昔单抗±低剂量化疗治疗这种恶性肿瘤。
Zotero 插件